Opus Point Partners Management as of Sept. 30, 2019
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 54 positions in its portfolio as reported in the September 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| iShares NASDAQ Biotechnology Index (IBB) | 37.8 | $21M | 210k | 99.51 | |
| Direxion Shs Etf Tr sp biotch bl | 5.6 | $3.1M | 100k | 30.90 | |
| Mettler-Toledo International (MTD) | 4.1 | $2.3M | 3.2k | 704.48 | |
| Bristol Myers Squibb (BMY) | 3.0 | $1.7M | 33k | 50.70 | |
| Seattle Genetics | 2.8 | $1.5M | 18k | 85.41 | |
| Illumina (ILMN) | 2.6 | $1.4M | 4.7k | 304.17 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.5 | $1.4M | 8.3k | 169.46 | |
| Ionis Pharmaceuticals (IONS) | 2.2 | $1.2M | 20k | 59.93 | |
| Alnylam Pharmaceuticals (ALNY) | 2.0 | $1.1M | 14k | 80.39 | |
| Alexion Pharmaceuticals | 1.8 | $973k | 9.9k | 97.96 | |
| Qiagen Nv | 1.7 | $951k | 29k | 32.95 | |
| Spark Therapeutics | 1.7 | $941k | 9.7k | 97.02 | |
| Fortress Biotech | 1.6 | $865k | 614k | 1.41 | |
| Proqr Thrapeutics N V shs euro (PRQR) | 1.4 | $798k | 139k | 5.76 | |
| Incyte Corporation (INCY) | 1.4 | $791k | 11k | 74.21 | |
| EXACT Sciences Corporation (EXAS) | 1.4 | $771k | 8.5k | 90.34 | |
| Regeneron Pharmaceuticals (REGN) | 1.2 | $677k | 2.4k | 277.57 | |
| BioMarin Pharmaceutical (BMRN) | 1.2 | $654k | 9.7k | 67.42 | |
| Deciphera Pharmaceuticals | 1.1 | $632k | 19k | 33.92 | |
| Ascendis Pharma A S (ASND) | 1.1 | $596k | 6.2k | 96.28 | |
| Celgene Corporation | 1.0 | $559k | 5.6k | 99.38 | |
| Uniqure Nv (QURE) | 1.0 | $560k | 14k | 39.40 | |
| Crispr Therapeutics (CRSP) | 1.0 | $542k | 13k | 41.02 | |
| Epizyme | 0.9 | $520k | 50k | 10.32 | |
| Amarin Corporation (AMRN) | 0.9 | $510k | 34k | 15.16 | |
| Blueprint Medicines (BPMC) | 0.9 | $498k | 6.8k | 73.45 | |
| Audentes Therapeutics | 0.9 | $487k | 17k | 28.09 | |
| G1 Therapeutics | 0.9 | $475k | 21k | 22.79 | |
| Global Blood Therapeutics In | 0.8 | $460k | 9.5k | 48.53 | |
| Biohaven Pharmaceutical Holding | 0.8 | $453k | 11k | 41.74 | |
| Arena Pharmaceuticals | 0.8 | $447k | 9.8k | 45.75 | |
| ACADIA Pharmaceuticals (ACAD) | 0.8 | $432k | 12k | 35.99 | |
| Gw Pharmaceuticals Plc ads | 0.8 | $423k | 3.7k | 115.13 | |
| Zogenix | 0.7 | $389k | 9.7k | 40.00 | |
| Macrogenics (MGNX) | 0.7 | $384k | 30k | 12.77 | |
| Intellia Therapeutics (NTLA) | 0.7 | $380k | 29k | 13.34 | |
| Bio-techne Corporation (TECH) | 0.6 | $303k | 1.6k | 195.36 | |
| Iqvia Holdings (IQV) | 0.5 | $297k | 2.0k | 149.62 | |
| Amgen (AMGN) | 0.5 | $294k | 1.5k | 193.68 | |
| Charles River Laboratories (CRL) | 0.5 | $280k | 2.1k | 132.58 | |
| Neurocrine Biosciences (NBIX) | 0.5 | $282k | 3.1k | 90.18 | |
| Checkpoint Therapeutics | 0.5 | $281k | 113k | 2.49 | |
| United Therapeutics Corporation (UTHR) | 0.5 | $279k | 3.5k | 79.76 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.5 | $264k | 13k | 20.01 | |
| Biogen Idec (BIIB) | 0.5 | $261k | 1.1k | 232.41 | |
| Gilead Sciences (GILD) | 0.5 | $259k | 4.1k | 63.45 | |
| Intercept Pharmaceuticals In | 0.5 | $261k | 3.9k | 66.48 | |
| Ligand Pharmaceuticals In (LGND) | 0.4 | $242k | 2.4k | 99.67 | |
| Exelixis (EXEL) | 0.4 | $232k | 13k | 17.67 | |
| Nektar Therapeutics (NKTR) | 0.4 | $235k | 13k | 18.18 | |
| Alkermes (ALKS) | 0.4 | $227k | 12k | 19.52 | |
| Ultragenyx Pharmaceutical (RARE) | 0.4 | $217k | 5.1k | 42.85 | |
| Fibrogen (FGEN) | 0.4 | $212k | 5.7k | 36.92 | |
| Recro Pharma | 0.2 | $126k | 11k | 11.10 |
